Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 128

1.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

2.

Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults.

Holdaway IM, Hunt P, Manning P, Cutfield W, Gamble G, Ninow N, Staples-Moon D, Moodie P, Metcalfe S.

Clin Endocrinol (Oxf). 2015 Jul;83(1):85-90. doi: 10.1111/cen.12691. Epub 2015 Feb 9.

PMID:
25523467
3.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.

4.

Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin.

Braatvedt G, Jennison E, Holdaway IM.

Clin Endocrinol (Oxf). 2014 Jan;80(1):80-4. doi: 10.1111/cen.12253. Epub 2013 Jun 20.

PMID:
23711285
5.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.

Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.

6.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.

Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.

7.

Mortality and morbidity in Cushing's syndrome in New Zealand.

Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ, Toomath RJ.

Clin Endocrinol (Oxf). 2011 Oct;75(4):436-42. doi: 10.1111/j.1365-2265.2011.04124.x.

PMID:
21609352
8.

Unmasking of undiagnosed pre-existing central diabetes insipidus after renal transplantation.

Kim DD, Holdaway IM.

Pituitary. 2012 Mar;15(1):106-9. doi: 10.1007/s11102-010-0259-y.

PMID:
20821268
9.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.

10.

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.

Holdaway IM, Bolland MJ, Gamble GD.

Eur J Endocrinol. 2008 Aug;159(2):89-95. doi: 10.1530/EJE-08-0267. Epub 2008 Jun 4.

PMID:
18524797
11.

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.

Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA; International Breast Cancer Study Group.

Ann Oncol. 2008 Aug;19(8):1393-401. doi: 10.1093/annonc/mdn123. Epub 2008 Apr 2.

12.

Excess mortality in acromegaly.

Holdaway IM.

Horm Res. 2007;68 Suppl 5:166-72. doi: 10.1159/000110617. Epub 2007 Dec 10. Review.

PMID:
18174739
13.

Acute retinal pigment epitheliitis associated with intravenous bisphosphonate.

Gilhotra JS, Gilhotra AK, Holdaway IM, Donaldson ML.

Br J Ophthalmol. 2006 Jun;90(6):798-9. No abstract available.

14.

Serum IGF-I levels are similar in Samoan, Māori and European populations despite differences in body composition.

Bagg W, Aoina J, Cross PA, Whalley GA, Gamble GD, Doughty RN, Holdaway IM.

Growth Horm IGF Res. 2006 Feb;16(1):57-60. Epub 2006 Jan 23.

PMID:
16431147
15.

Treatment of acromegaly.

Holdaway IM.

Horm Res. 2004;62 Suppl 3:79-92. Review.

PMID:
15539805
16.

Factors influencing mortality in acromegaly.

Holdaway IM, Rajasoorya RC, Gamble GD.

J Clin Endocrinol Metab. 2004 Feb;89(2):667-74.

PMID:
14764779
17.

Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging.

Dissanayake AM, Wilson JL, Holdaway IM, Reid IR.

Intern Med J. 2003 Dec;33(12):615-6. No abstract available.

PMID:
14656239
18.

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.

Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, Evans BD.

ANZ J Surg. 2003 Nov;73(11):905-8.

PMID:
14616567
19.

An unusual cause of hyperinsulinaemic hypoglycaemia syndrome.

Manning PJ, Espiner EA, Yoon K, Drury PL, Holdaway IM, Bowers A.

Diabet Med. 2003 Sep;20(9):772-6.

PMID:
12925060
20.

Long-term treatment outcome in acromegaly.

Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW.

Growth Horm IGF Res. 2003 Aug;13(4):185-92. Review.

PMID:
12914751

Supplemental Content

Loading ...
Support Center